ClinicalTrials.gg
TerminatedNCT04933695CodeBreaK201Updated Jul 13, 2026Results posted

A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment

A Phase 2 interventional study of Sotorasib in Non-small Cell Lung Cancer, sponsored by Amgen. Terminated at 67 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by Amgen · Phase 2, Interventional, and Treatment

Why this study was terminated
Futility

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing sotorasib in Carcinoma, Non-Small-Cell Lung — 8 open to participants now, 10 under way, 1 of them phase 3. sotorasib · Carcinoma, Non-Small-Cell Lung.

Enrollment
5th of 19
42 · median 24
Started
2022
with 8 others
Phase 2
10 of 19
4 open now
Registered
2nd of 19
by date
Lead sponsor
2 of 19
Amgen

Among the 19 studies testing sotorasib in Carcinoma, Non-Small-Cell Lung, this one is the 5th largest by enrollment, is one of 9 that started in 2022, is one of 10 in phase 2, and was the 2nd registered.

Carcinoma, Non-Small-Cell Lung

7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

8 of the 19 studies testing sotorasib in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About sotorasib

sotorasib: first FDA approval 2021 (LUMAKRAS), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing sotorasib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The main objective of this study is to evaluate the tumor objective response rate (ORR) assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria in participants who receive sotorasib at either 960 mg daily or 240 mg daily whose tumors are programmed death-ligand 1 (PD-L1) Tumor Proportion Score (TPS) \< 1% and/or harbor a serine/threonine kinase 11 (STK11) co-mutation, in a subgroup of participants with PD-L1 \< 1% and in a subgroup of participants with STK11 co-mutation.

03

Conditions studied

  • Non-small Cell Lung Cancer

Keywords

  • Non-small cell lung cancer
  • KRAS p.G12C
  • Sotorasib
  • AMG 510
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult (= or > 18 years old) with NSCLC
  • Untreated Stage IV disease. Participants who received or neoadjuvant anti-tumor therapy are eligible if the adjuvant/neoadjuvant therapy was completed greater than 12 months prior to the development of metastatic stage IV disease
  • documented metastatic NSCLC with KRAS G12C mutation (local confirmation)
  • Programmed death-ligand 1 () TPS Score \< 1% and/or serine/threonine kinase 11 (STK11) co-mutation (local confirmation)
  • (ECOG) score of 0 or 1
  • No active
  • per investigator interpretation using (RECIST) 1.1 criteria

Exclusion criteria

Exclusion Criteria:

  • Mixed small-cell lung cancer and NSCLC histology
  • Myocardial Infarction within 6 months of study Day 1
  • Use of proton-pump inhibitors (PPIs), histamine (H2) receptor antagonists (H2RA), strong inducers of cytochrome P450 (CYP) 3A4 () or known CYP3A4 sensitive substrates or P-gp substrates
  • Therapeutic or palliative radiation therapy within 2 weeks of study day 1
  • Unable to take oral medication
  • Unable to receive both iodinated contrast for computed tomography (CT) scans and gadolinium contrast for magnetic resonance imagine (MRI) scans
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Sotorasib: 960 mg Daily

    Participants with metastatic non-small cell lung cancer (NSCLC) with Kirsten rat sarcoma (KRAS) p.G12C mutation whose tumors express \< 1% programmed death-ligand 1 (PD-L1) and/or serine/threonine kinase 11 (STK11) mutation in need of first line treatment will be administered sotorasib 960 mg daily. Participants will be stratified by known presence of STK11 mutation.

    Drug: Sotorasib

  • Experimental
    Sotorasib: 240 mg Daily

    Participants with metastatic non-small cell lung cancer (NSCLC) with Kirsten rat sarcoma (KRAS) p.G12C mutation whose tumors express \< 1% programmed death-ligand 1 (PD-L1) and/or serine/threonine kinase 11 (STK11) mutation in need of first line treatment will be administered sotorasib 240 mg daily. Participants will be stratified by known presence of STK11 mutation.

    Drug: Sotorasib

Interventions

  • Oral tablet

    Also known as: AMG 510, LUMYKRAS, LUMAKRAS

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR)

    Objective response was defined as best overall response (BOR) of complete response (CR) or partial response (PR), as defined by RECIST 1.1. CR was defined as the disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis \<10 mm. PR was defined as at least a 30% decrease in the sum of diameter (SOD) of target lesions, taking as reference the baseline sum diameters. Progressive disease (PD) was defined as at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions. Responses were assessed based on BICR.

    Time frame: From the first dose of trial drug until min (last dose + 30 days, end of trial [EOT]); median [min, max] duration was 5.32 [0.8, 30.9] months

Secondary outcomes

  1. Disease Control Rate (DCR) Per RECIST Version 1.1 as Assessed by BICR

    DCR was defined as the percentage of participants with an OR or stable disease (SD) per RECIST v1.1. CR: disappearance of all target lesions. All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis to \<10 mm. PR: at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum of the longest diameter. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD: at least a 20% increase in sum of diameters of target lesions, taking as reference the smallest sum on study (this includes baseline sum if that is the smallest on study).

    Time frame: From randomization until EOT; median [min, max] time on trial was 9.72 [0.8, 38.0] months

  2. Duration of Response (DOR) Per RECIST Version 1.1 as Assessed by BICR

    DOR was defined as time from the first documentation of OR subsequently confirmed until the first documentation of PD or death due to any cause, whichever comes first. CR: disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (target or non-target) must have a reduction in their short axis \<10 mm. PR: at least a 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters. PD: at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions.

    Time frame: From randomization until EOT; median [min, max] time on trial was 9.72 [0.8, 38.0] months

  3. Time to Response (TTR) Per RECIST Version 1.1 as Assessed by BICR

    TTR was defined as time from first dose date to the first documentation of PR or CR subsequently confirmed. CR was defined as the disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis \<10 mm. PR was defined as at least a 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters. PD was defined as at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions.

    Time frame: From randomization until EOT; median [min, max] time on trial was 9.72 [0.8, 38.0] months

  4. Progression-free Survival (PFS) as Assessed by BICR

    PFS by BICR was defined as the time from first dose date to disease progression or death due to any cause (whichever comes first). PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the baseline SOD of target lesions.

    Time frame: From randomization until EOT; median [min, max] time on trial was 9.72 [0.8, 38.0] months

  5. Overall Survival (OS)

    OS was defined as the time from first dose date until event of death due to any cause.

    Time frame: From randomization until EOT; median [min, max] time on trial was 9.72 [0.8, 38.0] months

  6. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-related TEAEs

    TEAEs are AEs starting on or after the first dose of sotorasib as determined by the flag indicating if the AE started prior to the first dose on the Events case report form (CRF) and up to and including 30 days after the last dose of sotorasib or the EOT date, whichever is earlier. A treatment-related TEAE is any TEAE with the relationship flag on the events CRF indicating there is a reasonable possibility that the event may have been caused by investigational medicinal product. Clinically significant changes in vital signs, electrocardiograms (ECGs), and clinical laboratory tests were included as TEAEs.

    Time frame: From the first dose of trial drug until min (last dose + 30 days, EOT); median [min, max] duration was 5.32 [0.8, 30.9] months

  7. Plasma Concentration of Sotorasib

    Blood samples were collected at specified timepoints.

    Time frame: Cycles 1 and 2: Day 1 pre-dose and 1 hour post-dose; Cycles 3, 4 and, 5: Day 1 pre-dose (cycle length = 21 days)

07

Results

Posted Jul 13, 2026
Limitations and caveats
This study with sotorasib monotherapy was discontinued due to strategic reasons.

Participant flow

A total of 42 participants were enrolled across 17 trial centers in the United States and Europe from January 2022 to May 2025.

Participant flow — Overall Study
MilestoneSotorasib 240 mgSotorasib 960 mg
Started2121
Completed00
Not completed2121
Withdrew: Withdrawal of consent from trial40
Withdrew: Decision by sponsor25
Withdrew: Death1516

Outcome measures

PrimaryObjective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR)

Objective response was defined as best overall response (BOR) of complete response (CR) or partial response (PR), as defined by RECIST 1.1. CR was defined as the disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis \<10 mm. PR was defined as at least a 30% decrease in the sum of diameter (SOD) of target lesions, taking as reference the baseline sum diameters. Progressive disease (PD) was defined as at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions. Responses were assessed based on BICR.

Time frame:
From the first dose of trial drug until min (last dose + 30 days, end of trial [EOT]); median [min, max] duration was 5.32 [0.8, 30.9] months
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR)
percentage of participantsSotorasib
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR)26.8 (14.2 to 42.9)
SecondaryDisease Control Rate (DCR) Per RECIST Version 1.1 as Assessed by BICR

DCR was defined as the percentage of participants with an OR or stable disease (SD) per RECIST v1.1. CR: disappearance of all target lesions. All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis to \<10 mm. PR: at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum of the longest diameter. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD: at least a 20% increase in sum of diameters of target lesions, taking as reference the smallest sum on study (this includes baseline sum if that is the smallest on study).

Time frame:
From randomization until EOT; median [min, max] time on trial was 9.72 [0.8, 38.0] months
Reported as:
Number · percentage of participants
Disease Control Rate (DCR) Per RECIST Version 1.1 as Assessed by BICR
percentage of participantsSotorasib
Disease Control Rate (DCR) Per RECIST Version 1.1 as Assessed by BICR73.2 (57.1 to 85.8)
SecondaryDuration of Response (DOR) Per RECIST Version 1.1 as Assessed by BICR

DOR was defined as time from the first documentation of OR subsequently confirmed until the first documentation of PD or death due to any cause, whichever comes first. CR: disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (target or non-target) must have a reduction in their short axis \<10 mm. PR: at least a 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters. PD: at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions.

Time frame:
From randomization until EOT; median [min, max] time on trial was 9.72 [0.8, 38.0] months
Reported as:
Median · months
Duration of Response (DOR) Per RECIST Version 1.1 as Assessed by BICR
monthsSotorasib
Duration of Response (DOR) Per RECIST Version 1.1 as Assessed by BICR7.2 (2.8 to NA)
SecondaryTime to Response (TTR) Per RECIST Version 1.1 as Assessed by BICR

TTR was defined as time from first dose date to the first documentation of PR or CR subsequently confirmed. CR was defined as the disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis \<10 mm. PR was defined as at least a 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters. PD was defined as at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions.

Time frame:
From randomization until EOT; median [min, max] time on trial was 9.72 [0.8, 38.0] months
Reported as:
Median · months
Time to Response (TTR) Per RECIST Version 1.1 as Assessed by BICR
monthsSotorasib
Time to Response (TTR) Per RECIST Version 1.1 as Assessed by BICR1.5 (1 to 6)
SecondaryProgression-free Survival (PFS) as Assessed by BICR

PFS by BICR was defined as the time from first dose date to disease progression or death due to any cause (whichever comes first). PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the baseline SOD of target lesions.

Time frame:
From randomization until EOT; median [min, max] time on trial was 9.72 [0.8, 38.0] months
Reported as:
Median · months
Progression-free Survival (PFS) as Assessed by BICR
monthsSotorasib
Progression-free Survival (PFS) as Assessed by BICR4.5 (2.7 to 8.3)
SecondaryOverall Survival (OS)

OS was defined as the time from first dose date until event of death due to any cause.

Time frame:
From randomization until EOT; median [min, max] time on trial was 9.72 [0.8, 38.0] months
Reported as:
Median · months
Overall Survival (OS)
monthsSotorasib
Overall Survival (OS)11.8 (7.7 to 16.4)
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-related TEAEs

TEAEs are AEs starting on or after the first dose of sotorasib as determined by the flag indicating if the AE started prior to the first dose on the Events case report form (CRF) and up to and including 30 days after the last dose of sotorasib or the EOT date, whichever is earlier. A treatment-related TEAE is any TEAE with the relationship flag on the events CRF indicating there is a reasonable possibility that the event may have been caused by investigational medicinal product. Clinically significant changes in vital signs, electrocardiograms (ECGs), and clinical laboratory tests were included as TEAEs.

Time frame:
From the first dose of trial drug until min (last dose + 30 days, EOT); median [min, max] duration was 5.32 [0.8, 30.9] months
Reported as:
Number · count of participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-related TEAEs
count of participantsSotorasib 240 mgSotorasib 960 mg
TEAEs1921
Treatment-related TEAEs1311
SecondaryPlasma Concentration of Sotorasib

Blood samples were collected at specified timepoints.

Time frame:
Cycles 1 and 2: Day 1 pre-dose and 1 hour post-dose; Cycles 3, 4 and, 5: Day 1 pre-dose (cycle length = 21 days)
Reported as:
Mean · ng/mL
Plasma Concentration of Sotorasib
ng/mLSotorasib 240 mg QDSotorasib 960 mg QD
Cycle 1 Day 1 pre-dose0.00 ± 0.000.00 ± 0.00
Cycle 1 Day 1: 1 hour6840 ± 406011600 ± 6880
Cycle 2 Day 1 pre-dose394 ± 858883 ± 2140
Cycle 2 Day 1: 1 hour4870 ± 32007340 ± 3760
Cycle 3 Day 1: pre-dose347 ± 698259 ± 331
Cycle 4 Day 1: pre-dose366 ± 590255 ± 277
Cycle 5 Day 1: pre-dose211 ± 353164 ± 153

Adverse events

Collected over For mortality reporting: from randomization until EOT; median [min, max] time on trial was 9.72 [0.8, 38.0] months. For AE reporting: from the first dose of trial drug until min(last dose + 30 days, EOT); median [min, max] duration was 5.32 [0.8, 30.9] months.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sotorasib 240 mg15/21 (71.4%)9/21 (42.9%)18/21 (85.7%)
Sotorasib 960 mg16/21 (76.2%)9/21 (42.9%)20/21 (95.2%)
Most frequent serious events
Showing 10 of 28
Most frequent serious events
EventSotorasib 240 mgSotorasib 960 mg
General physical health deteriorationGeneral disorders0/212/21
PneumoniaInfections and infestations2/210/21
DyspnoeaRespiratory, thoracic and mediastinal disorders0/212/21
Pleural effusionRespiratory, thoracic and mediastinal disorders0/212/21
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/212/21
AnaemiaBlood and lymphatic system disorders1/210/21
Iron deficiency anaemiaBlood and lymphatic system disorders0/211/21
Acute cardiac eventCardiac disorders0/211/21
Atrial fibrillationCardiac disorders0/211/21
Cardiac failureCardiac disorders1/210/21
Most frequent other events
Showing 10 of 100
Most frequent other events
EventSotorasib 240 mgSotorasib 960 mg
DiarrhoeaGastrointestinal disorders7/217/21
Chest painGeneral disorders2/216/21
NauseaGastrointestinal disorders3/215/21
VomitingGastrointestinal disorders4/211/21
FatigueGeneral disorders4/212/21
Back painMusculoskeletal and connective tissue disorders3/214/21
DyspnoeaRespiratory, thoracic and mediastinal disorders4/212/21
Productive coughRespiratory, thoracic and mediastinal disorders1/214/21
AnaemiaBlood and lymphatic system disorders2/213/21
ConstipationGastrointestinal disorders3/212/21

Baseline characteristics

All randomized participants. As per-planned analysis, the data for baseline measures were collected, analyzed and reported as a single cohort.

Age, Continuous
Age, Continuous(years)Sotorasib
Mean66.5 ± 9.8
Sex: Female, Male
Sex: Female, Male(Participants)Sotorasib
Female13
Male29
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Sotorasib
White41
Other1
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Sotorasib
Not Hispanic or Latino42
08

Study locations

67 sites
  • Alabama Oncology
    Birmingham, Alabama 35243, United States
  • Arizona Oncology Associates Professional Corporation
    Tucson, Arizona 85711, United States
  • City of Hope at Long Beach Elm
    Duarte, California 91010, United States
  • City of Hope National Medical Center
    Duarte, California 91010, United States
  • Baptist MD Anderson Cancer Center
    Jacksonville, Florida 32207, United States
  • Northwest Georgia Oncology Centers PC
    Marietta, Georgia 30060, United States
  • Indiana University Melvin and Bren Simon Cancer Center
    Indianapolis, Indiana 46202, United States
  • Baptist Health Lexington
    Lexington, Kentucky 40503, United States
  • Frederick Memorial Hospital
    Frederick, Maryland 21702, United States
  • Englewood Hospital and Medical Center
    Englewood, New Jersey 07631, United States
  • Rutgers Cancer Institute of New Jersey
    New Brunswick, New Jersey 08901, United States
  • Laura and Isaac Perlmutter Cancer Center at New York University Langone
    New York, New York 10016, United States
  • Northport Veterans Affairs Medical Center
    Northport, New York 11768, United States
  • State University of New York Upstate Medical University
    Syracuse, New York 13210, United States
  • James J Peters VA Medical Center
    The Bronx, New York 10468, United States
  • Duke University Medical Center, Morris Cancer Clinic
    Durham, North Carolina 27710, United States
  • Allegheny Health Network Cancer Institute at Allegheny General Hospital
    Pittsburgh, Pennsylvania 15212, United States
  • University of Pittsburgh Medical Center Cancer Pavillion
    Pittsburgh, Pennsylvania 15232, United States
  • Medical University of South Carolina, Hollings Cancer Center
    Charleston, South Carolina 29425, United States
  • Texas Oncology - Medical City Dallas
    Dallas, Texas 75230-2510, United States
  • Texas Oncology - Plano East
    Dallas, Texas 75230-2510, United States
  • Texas Oncology-Dallas Presbyterian Hospital
    Dallas, Texas 75231, United States
  • Texas Oncology - Flower Mound
    Dallas, Texas 75234, United States
  • Texas Oncology - Baylor
    Dallas, Texas 75246, United States
  • Texas Oncology-Denton
    Denton, Texas 76201, United States
  • Oncology Consultants PA
    Houston, Texas 77030, United States
  • University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Texas Oncology- Mckinney
    McKinney, Texas 75071, United States
  • Texas Oncology - Northeast Texas
    Paris, Texas 75460-5004, United States
  • Gundersen Health System
    La Crosse, Wisconsin 54601, United States
  • Universite Catholique de Louvain Cliniques Universitaires Saint Luc
    Brussels, 1200, Belgium
  • Universitair Ziekenhuis Antwerpen
    Edegem, 2650, Belgium
  • Jessa Ziekenhuis - Campus Virga Jesse
    Hasselt, 3500, Belgium
  • Centre Hospitalier Universitaire de Liege - Sart Tilman
    Liège, 4000, Belgium
  • Odense Universitetshospital
    Odense C, 5000, Denmark
  • Institut Sainte Catherine
    Avignon, 84918, France
  • Centre Hospitalier Universitaire Régional de Lille - Hôpital Albert Calmette
    Lille, 59037, France
  • Centre Hospitalier Universitaire de Limoges - Hopital Dupuytren
    Limoges, 87042, France
  • Centre Hospitalier Universitaire de Montpellier - Val d Aurelle
    Montpellier, 34298, France
  • Hopital Cochin
    Paris, 75014, France
  • Centre Hospitalier Universitaire de Bordeaux - Hopital Haut Leveque
    Pessac, 33604, France
  • Centre Hospitalier Universitaire de Rennes - Hopital Pontchaillou
    Rennes, 35033, France
  • Centre Hospitalier de Nantes - Hôpital Nord Laënnec
    Saint-Herblain, 44800, France
  • Hôpital Sainte Musse
    Toulon, 83056, France
  • Centre Hospitalier Universitaire de Toulouse - Hopital Larrey
    Toulouse, 31059, France
  • Universitätsklinikum Köln
    Cologne, 50937, Germany
  • Klinikum und Fachbereich Medizin Johann Wolfgang Goethe-Universität Frankfurt am Main
    Frankfurt am Main, 60590, Germany
  • Asklepios - Fachkliniken München-Gauting
    Gauting, 82130, Germany
  • Azienda Socio Sanitaria Territoriale di Monza Ospedale San Gerardo
    Monza (MB), 20900, Italy
  • Azienda Ospedaliera di Rilievo Nazionale Specialistica dei Colli Monaldi
    Naples, 80131, Italy
  • Azienda Ospedaliera Universitaria San Luigi Gonzaga
    Orbassano (TO), 10043, Italy
  • Istituti Fisioterapici Ospitalieri Regina Elena San Gallicano
    Rome, 00144, Italy
  • Nederlands Kanker Instituut Antoni van Leeuwenhoekziekenhuis
    Amsterdam, 1066 CX, Netherlands
  • Hospital del Mar
    Barcelona, Catalonia 08003, Spain
  • Hospital de la Santa Creu i Sant Pau
    Barcelona, Catalonia 08041, Spain
  • Hospital Clinico Universitario de Santiago
    Santiago de Compostela, Galicia 15706, Spain
  • Hospital Universitario Puerta de Hierro Majadahonda
    Majadahonda, Madrid 28222, Spain
  • Hospital Universitari i Politecnic La Fe
    Valencia, Valencia 46026, Spain
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
  • Gavle Sjukhus
    Gävle, 801 87, Sweden
  • Sahlgrenska Universitetssjukhuset
    Gothenburg, 413 45, Sweden
  • Universitetssjukhuset i Linkoping
    Linköping, 581 85, Sweden
  • Skanes Universitetssjukhus
    Lund, 221 85, Sweden
  • Norrlands Universitetssjukhus
    Umeå, 901 85, Sweden
  • Gazi Universitesi Saglik Arastirma ve Uygulama Merkezi Gazi Hastanesi
    Ankara, 06560, Turkey (Türkiye)
  • Trakya Universitesi Saglik Arastirma ve Uygulama Merkezi
    Edirne, 22030, Turkey (Türkiye)
  • Koc Universitesi Hastanesi
    Istanbul, 34010, Turkey (Türkiye)
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2022 to primary completion in May 2025, 40 months.

Results were first posted in Jul 2026, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2021
First posted
Jun 22, 2021
StartActual
Jan 28, 2022
Primary completionActual
May 28, 2025
CompletionActual
May 28, 2025
Results first posted
Jul 13, 2026
Last update
Jul 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04933695
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Jun 22, 2021
Start date
Jan 28, 2022
Primary completion
May 28, 2025
Completion
May 28, 2025
Results posted
Jul 13, 2026
Last update
Jul 13, 2026

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sotorasib

Start the discussion